John Sourbeer
Stock Analyst at UBS
(0.73)
# 3,859
Out of 4,931 analysts
39
Total ratings
36.84%
Success rate
-21.75%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $48.16 | +3.82% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $241.25 | +32.64% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $157.32 | +52.56% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $8.50 | +29.41% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $24.47 | -3.96% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $24.11 | +86.64% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.32 | +51.52% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $94.50 | +53.44% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $428.29 | +12.07% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $30.72 | +232.03% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $12.59 | +297.14% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $131.84 | -2.91% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $48.16
Upside: +3.82%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $241.25
Upside: +32.64%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $157.32
Upside: +52.56%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $8.50
Upside: +29.41%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $24.47
Upside: -3.96%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $24.11
Upside: +86.64%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.32
Upside: +51.52%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $94.50
Upside: +53.44%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $428.29
Upside: +12.07%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $30.72
Upside: +232.03%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $12.59
Upside: +297.14%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $131.84
Upside: -2.91%